@article{10902/34462,
year = {2024},
url = {https://hdl.handle.net/10902/34462},
abstract = {The complement (C) system is implicated in the etiopathogenesis of rheumatoid arthritis (RA). However, there is a lack of studies characterizing all three C pathways in RA patients. This study aimed to evaluate the association between an in-depth examination of the C system and RA patient characteristics, focusing on disease activity and the presence of rheumatoid factor and anti-citrullinated protein autoantibodies (ACPA). In a cohort of 430 RA patients, functional assays of the three C pathways (classical, alternative, and lectin) and serum levels of their components were assessed. Components included C1q (classical); factor D and properdin (alternative); lectin (lectin); C1-inhibitor; C2, C4, and C4b (classical and lectin); C3, C3a, and C4b (common); and C5, C5a, and C9 (terminal). A multivariable linear regression analysis showed significant positive correlations between C-reactive protein and C system proteins and functional assays, especially in the terminal and common pathways. Disease activity, measured by scores with or without acute phase reactants, positively correlated with the classical pathway functional test and terminal pathway products. Conversely, rheumatoid factor or ACPA presence was associated with lower classical pathway values and decreased C3a and C4b levels, suggesting complement depletion. In conclusion, RA disease activity increases C molecules and functional complement assays, while rheumatoid factor or ACPA positivity is linked to C consumption. Our study offers a detailed analysis of the complement system?s role in RA, potentially guiding the development of more targeted and effective treatment strategies.},
organization = {Funding: This study was funded by a grant to IF-A by Instituto de Salud Carlos III (ISCIII) through the project PI20/00084 and co-funded by the European Union.
Acknowledgments: Iván Ferraz-Amaro would like to acknowledge that he has received grants/research supports from Abbott, MSD, Janssen, and Roche, as well as consultation fees from company-sponsored speakers’ bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and M.A. González-Gay received consultation fees/participation from a company-sponsored speakers’ bureau from GSK.},
publisher = {MDPI},
publisher = {International Journal of Molecular Sciences, 2024, 25, 8360},
title = {Complete description of the three pathways of the complement system in a series of 430 patients with rheumatoid arthritis},
author = {Rodríguez-González, Dara and Carcía-González, María and Gómez-Bernal, Fuensanta and Quevedo-Abeledo, Juan C. and González-Rivero, Agustín F. and Fernández-Cladera, Yolanda and González López, Elena and Ocejo Viñals, Javier Gonzalo and Jiménez-Sosa, Alejandro and González-Toledo, Beatriz and González-Gay Mantecón, Miguel Ángel},
}